ESMO 2023: vídeos e entrevistas

22 vídeos do ESMO 2023 publicados por ESMO, OncLive, ecancer. Atualizado em 20/11/2026.

Ver no OncoTV com filtros

Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial CancerOncLive · 03/07/2024 · 1:18 · apoio da indústriaCAR-T therapy and impact to cancer patient outcomes and experience of treatmentecancer · 20/02/2024 · 7:32 · apoio da indústriaTrial investigates multiparametric prognostic score in early HR+/HER2- breast cancerecancer · 20/02/2024 · 3:02 · apoio da indústriaCabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumoursecancer · 20/02/2024 · 2:48 · apoio da indústria2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvan...ecancer · 20/02/2024 · 2:21 · apoio da indústriaPembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally ...ecancer · 20/02/2024 · 2:38 · apoio da indústriaAdjuvant radiotherapy has no benefit following radical prostatectomyecancer · 20/02/2024 · 3:31 · apoio da indústriaFeasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemothe...ecancer · 20/02/2024 · 3:00 · apoio da indústriaTisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervica...ecancer · 20/02/2024 · 2:47 · apoio da indústriaDatopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancerecancer · 20/02/2024 · 3:36 · apoio da indústriaEnfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancerecancer · 20/02/2024 · 6:01 · apoio da indústriaBelzutifan improves PFS, ORR in clear cell renal cell carcinomaecancer · 20/02/2024 · 2:23 · apoio da indústriaEffects of short-term fasting on quality of life as an add-on option during chemotherapyecancer · 20/02/2024 · 5:21 · apoio da indústriaBelzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCCecancer · 20/02/2024 · 1:52 · apoio da indústriaSelpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancerecancer · 20/02/2024 · 4:57 · apoio da indústriaCheckMate-77T: Perioperative nivolumab benefit for NSCLCecancer · 20/02/2024 · 14:05 · apoio da indústriaESMO Patient Guides: Let's talk about oesophageal and stomach cancersESMO · 20/12/2023 · 57:38ESMO Congress 2023 Patient Advocacy Track Testimonial with André DeschampsESMO · 18/12/2023 · 1:14ESMO Congress 2023 Patient Advocacy Track Testimonial with Anne Marie BairdESMO · 18/12/2023 · 1:57ESMO Congress 2023 Patient Advocacy Track Testimonial with Barbara MossESMO · 18/12/2023 · 2:15ESMO Congress 2023 Patient Advocacy Track Testimonial with Jana PelouchovaESMO · 18/12/2023 · 1:42ESMO Congress 2023 Patient Advocacy Track Testimonial with Natacha BolanosESMO · 18/12/2023 · 1:51